Name: Prescient Therapeutics (PTX) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

PTX

Pharmaceuticals, Biotechnology & Life Sciences

Prescient Therapeutics

Short interest: <0.01%; 0.00 pp 30d; as of 14 Apr 2026
Reported shorts: 11K
Shares on issue: 1.052B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Prescient Therapeutics

Prescient Therapeutics is a clinical-stage oncology company focused on developing targeted therapies for cancer treatment. Their business model centers around advancing a diversified pipeline of assets, including PTX-100 in Phase 2a clinical development, and next-generation cell therapy platforms like OmniCAR and CellPryme, sourced from collaborations with leading research institutions.

Company profile →

Prescient Therapeutics (ASX:PTX) has <0.01% of its shares on issue reported as short positions as of 14 Apr 2026, or about 10,996 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.61% in January 2020. PTX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 43, 2026.

Strategy fit

How each stock picker strategy reads PTX today

Zanger BreakoutNot a candidate
CAN SLIMNot a candidate
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 15rank 1145 of 1748

Prices to 28 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

PTX fundamentals

In the year to 30 Jun 2026, Prescient Therapeutics (ASX:PTX) recorded revenue of A$138.5K and a net loss after tax of A$7.0M. A year earlier it recorded revenue of A$225.6K and a net loss after tax of A$7.3M. Year-on-year growth: revenue −38.6% (FY). Net margin −5,056.4%, return on equity −54.7% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 29 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →